Published in AIDS Patient Care STDS on March 29, 2011
Barriers and facilitators to testing, treatment entry, and engagement in care by HIV-positive women of color. AIDS Patient Care STDS (2013) 1.15
"We weren't using condoms because we were trying to conceive": the need for reproductive counseling for HIV-positive women in clinical care. AIDS Patient Care STDS (2012) 1.13
Engaging HIV care providers in conversations with their reproductive-age patients about fertility desires and intentions: a historical review of the HIV epidemic in the United States. Am J Public Health (2013) 1.11
Pregnancy intentions among women living with HIV in the United States. J Acquir Immune Defic Syndr (2014) 1.07
Barriers to HIV care for women of color living in the Southeastern US are associated with physical symptoms, social environment, and self-determination. AIDS Patient Care STDS (2013) 1.05
Preconception and contraceptive care for women living with HIV. Infect Dis Obstet Gynecol (2012) 0.99
HIV-Related discrimination in European health care settings. AIDS Patient Care STDS (2014) 0.90
Desire for pregnancy and risk behavior in young HIV-positive women. AIDS Patient Care STDS (2012) 0.90
HIV providers' perceptions of and attitudes toward female versus male patients. AIDS Patient Care STDS (2012) 0.87
General and health-related Internet use among an urban, community-based sample of HIV-positive women: implications for intervention development. AIDS Care (2014) 0.87
Providers' perspectives on preconception counseling and safer conception for HIV-infected women. AIDS Care (2015) 0.84
Perspectives on safer conception practices and preconception counseling among women living with HIV. Health Care Women Int (2015) 0.83
The role of maternal, health system, and psychosocial factors in prevention of mother-to-child transmission failure in the era of programmatic scale up in western Kenya: a case control study. AIDS Patient Care STDS (2015) 0.81
HIV-infected Women's Perspectives on the Use of the Internet for Social Support: A Potential Role for Online Group-based Interventions. J Assoc Nurses AIDS Care (2014) 0.80
Provider Attitudes toward Discussing Fertility Intentions with HIV-Infected Women and Serodiscordant Couples in the USA. J AIDS Clin Res (2014) 0.79
Fertility Desires among Women Living with HIV. PLoS One (2016) 0.77
Prevalence of Drug Resistance and Associated Mutations in a Population of HIV-1(+) Puerto Ricans: 2006-2010. AIDS Res Treat (2012) 0.76
"Out of All of this Mess, I Got a Blessing": Perceptions and Experiences of Reproduction and Motherhood in African American Women Living With HIV. J Assoc Nurses AIDS Care (2015) 0.76
Lights and Shadows about the Effectiveness of IVF in HIV Infected Women: A Systematic Review. Infect Dis Obstet Gynecol (2015) 0.75
Shaping the Conversation: A Secondary Analysis of Reproductive Decision-Making Among Black Mothers with HIV. Clin Med Insights Womens Health (2016) 0.75
Gender Differences in Psychosocial Factors Associated with HIV Viral Suppression Among African-American Injection Drug Users. AIDS Behav (2016) 0.75
Parenting Among Adolescents and Young Adults with Human Immunodeficiency Virus Infection in the United States: Challenges, Unmet Needs, and Opportunities. AIDS Patient Care STDS (2016) 0.75
How are women living with HIV in France coping with their perceived side effects of antiretroviral therapy? Results from the EVE study. PLoS One (2017) 0.75
The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology (1998) 12.32
Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr (2002) 7.79
HIV prevalence estimates--United States, 2006. MMWR Morb Mortal Wkly Rep (2008) 7.76
Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA (2001) 5.52
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr (2010) 2.64
HIV infection in women in the United States: status at the Millennium. JAMA (2001) 2.51
A qualitative study of the barriers and facilitators to retention-in-care among HIV-positive women in the rural southeastern United States: implications for targeted interventions. AIDS Patient Care STDS (2010) 1.81
Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med (2010) 1.71
Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr (2008) 1.65
Social support, coping, and medication adherence among HIV-positive women with depression living in rural areas of the southeastern United States. AIDS Patient Care STDS (2007) 1.65
Do HIV-infected women want to discuss reproductive plans with providers, and are those conversations occurring? AIDS Patient Care STDS (2010) 1.56
Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109). Clin Pharmacol Ther (2008) 1.56
Quality of life in HIV-infected women in the south-eastern United States. AIDS Care (1997) 1.46
Determinants of accrual of women to a large, multicenter clinical trials program of human immunodeficiency virus infection. The AIDS Clinical Trials Group. J Acquir Immune Defic Syndr (1993) 1.31
Relationships between stigma, social support, and depression in HIV-infected African American women living in the rural Southeastern United States. J Assoc Nurses AIDS Care (2009) 1.30
Update: AIDS among women--United States, 1994. MMWR Morb Mortal Wkly Rep (1995) 1.14
Gender differences in the diagnosis and treatment of HIV. Gend Med (2007) 1.04
Barriers to health-seeking behaviors for women infected with HIV. Nursingconnections (1996) 0.99
Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS (2007) 0.99
Clinical care issues for women living with HIV and AIDS in the United States. AIDS Res Hum Retroviruses (2001) 0.98
Patterns of risk of depressive symptoms among HIV-positive women in the southeastern United States. J Assoc Nurses AIDS Care (2006) 0.86
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA (2010) 9.26
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA (2002) 2.96
Development of national and multiagency HIV care quality measures. Clin Infect Dis (2010) 2.79
Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS (2002) 2.59
AIDS in America--forgotten but not gone. N Engl J Med (2010) 2.56
Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clin Infect Dis (2004) 2.17
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis (2011) 2.12
Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med (2003) 2.02
Spirituality and religion in patients with HIV/AIDS. J Gen Intern Med (2006) 1.99
Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob Agents Chemother (2002) 1.75
The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS (2004) 1.73
Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med (2010) 1.71
Clinical impact of patient population differences and genomic variation in efavirenz therapy. AIDS (2008) 1.71
Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr (2005) 1.67
Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother (2005) 1.61
Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients. J Infect Dis (2004) 1.52
Coronary heart disease in people infected with HIV. Cleve Clin J Med (2010) 1.52
Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087. J Clin Lipidol (2010) 1.50
Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. J Infect Dis (2004) 1.48
Addressing research priorities for prevention of HIV infection in the United States. Clin Infect Dis (2010) 1.46
Awareness of post-exposure HIV prophylaxis in high-risk men who have sex with men in New York City. Sex Transm Infect (2011) 1.43
Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis (2005) 1.43
Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. J Infect Dis (2013) 1.26
Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr (2008) 1.15
Recruitment and retention of diverse populations in antiretroviral clinical trials: practical applications from the gender, race and clinical experience study. J Womens Health (Larchmt) (2011) 1.15
A randomized study of serial telephone call support to increase adherence and thereby improve virologic outcome in persons initiating antiretroviral therapy. J Infect Dis (2005) 1.12
Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study. J Acquir Immune Defic Syndr (2013) 1.11
Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis (2002) 1.07
A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS (2010) 1.05
Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148. Antivir Ther (2006) 1.05
Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis (2002) 1.03
HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study. Clin Infect Dis (2004) 1.03
Retention strategies and factors associated with missed visits among low income women at increased risk of HIV acquisition in the US (HPTN 064). AIDS Patient Care STDS (2014) 0.99
Tipranavir: a new option for the treatment of drug-resistant HIV infection. Clin Infect Dis (2007) 0.97
Care for transgender persons. JAMA (2013) 0.97
Change in quality of life after being diagnosed with HIV: a multicenter longitudinal study. AIDS Patient Care STDS (2009) 0.96
Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211. Clin Infect Dis (2009) 0.96
Global pharmacovigilance for antiretroviral drugs: overcoming contrasting priorities. PLoS Med (2011) 0.96
Health-related quality of life predicts survival, cytomegalovirus disease, and study retention in clinical trial participants with advanced HIV disease. J Clin Epidemiol (2003) 0.96
HIV diversity as a biomarker for HIV incidence estimation: including a high-resolution melting diversity assay in a multiassay algorithm. J Clin Microbiol (2013) 0.95
Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). J Acquir Immune Defic Syndr (2007) 0.95
Neuropsychiatric complications of antiretroviral therapy. Drug Saf (2006) 0.94
Changes in religiousness and spirituality attributed to HIV/AIDS: are there sex and race differences? J Gen Intern Med (2006) 0.94
The changing face of HIV care: common things really are common. Ann Intern Med (2006) 0.94
Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clin Pharmacol Ther (2005) 0.93
Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production. Arterioscler Thromb Vasc Biol (2009) 0.92
Prevention strategies for cardiovascular disease in HIV-infected patients. Circulation (2008) 0.91
Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. Clin Infect Dis (2004) 0.90
Glycated Hemoglobin A(1c) as screening for diabetes mellitus in HIV-infected individuals. AIDS Patient Care STDS (2012) 0.89
Characteristics of multiple and concurrent partnerships among women at high risk for HIV infection. J Acquir Immune Defic Syndr (2014) 0.89
HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients. AIDS (2002) 0.89
Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229. AIDS (2010) 0.86
Perceptions of Community HIV/STI Risk Among U.S Women Living in Areas with High Poverty and HIV Prevalence Rates. J Health Care Poor Underserved (2015) 0.85
Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort. J Acquir Immune Defic Syndr (2014) 0.85
Comparison of direct and indirect measurement of LDL-C in HIV-infected individuals: ACTG 5087. HIV Clin Trials (2007) 0.85
Modeling the impact of interventions along the HIV continuum of care in Newark, New Jersey. Clin Infect Dis (2013) 0.85
Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy. J Acquir Immune Defic Syndr (2013) 0.83
Nonnucleoside reverse transcriptase inhibitor resistance among antiretroviral-naive HIV-positive pregnant women. J Acquir Immune Defic Syndr (2003) 0.83
Pharmacokinetics of indinavir and nelfinavir in treatment-naive, human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother (2004) 0.83
Pulmonary cryptococcosis in normal hosts: treat or observe? Chest (2003) 0.83
Management of dyslipidemia in HIV-infected patients. Clin Lipidol (2011) 0.83
Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors. Clin Pharmacol Ther (2003) 0.82
Cardiac risk: not so simple. J Infect Dis (2010) 0.82
Cardiovascular and Endothelial Disease in HIV Infection. Curr Infect Dis Rep (2005) 0.82
Dyslipidemia in HIV patients. Cleve Clin J Med (2005) 0.82
Discontinuation of antiretroviral therapy postpartum: no evidence for altered viral set point. J Acquir Immune Defic Syndr (2007) 0.81
Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients. ISRN Gastroenterol (2011) 0.81
Letter in response to the new SHEA guideline for healthcare workers with hepatitis B virus, hepatitis C virus, and/or human immunodeficiency virus. Infect Control Hosp Epidemiol (2010) 0.80
Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir. J Acquir Immune Defic Syndr (2014) 0.80
Hyperparathyroidism and complications associated with vitamin D deficiency in HIV-infected adults in New York City, New York. AIDS Res Hum Retroviruses (2012) 0.79
Pafuramidine for Pneumocystis jiroveci pneumonia in HIV-infected individuals. Expert Rev Anti Infect Ther (2007) 0.79
Insights on GRACE (Gender, Race, And Clinical Experience) from the patient's perspective: GRACE participant survey. AIDS Patient Care STDS (2013) 0.79
GM-CSF Fails to Improve Immune Responses to Booster Hepatitis B Vaccination in HIV-Infected Individuals. Open Virol J (2011) 0.78
Cure of acute hepatitis C in HIV co-infection? J Clin Gastroenterol (2004) 0.78
Darunavir : a nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection. Expert Opin Pharmacother (2012) 0.78
How do patients with HIV/AIDS understand and respond to health value questions? J Gen Intern Med (2006) 0.77
Concerns regarding a randomized study of the timing of antiretroviral therapy in zimbabweans with AIDS and acute cryptococcal meningitis. Clin Infect Dis (2010) 0.77
High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection. AIDS (2011) 0.77
Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV. AIDS (2017) 0.76
The case for expanding human immunodeficiency virus testing. Mayo Clin Proc (2006) 0.75
HIV counseling and testing for household members of HIV-infected individuals in Africa: should prevention programs focus on home-based rather than clinic-based outreach? Curr HIV/AIDS Rep (2011) 0.75
The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit. PLoS One (2013) 0.75
Risk factors for tuberculin skin test conversion among HIV-infected patients in New York City. Int J Infect Dis (2012) 0.75
Didanosine, interferon-alfa, and ribavirin. AIDS (2004) 0.75
A tale of two fungi in a person with HIV. MedGenMed (2006) 0.75
Clash of the microbes: let's bring back the good guys. J Clin Invest (2013) 0.75
Case files from the Bellevue Hospital Center at New York University--lipoatrophy following long-term antiretroviral therapy. MedGenMed (2005) 0.75
Report from the 15th Retrovirus Conference. Parsing the options from comparative trials of initial antiretroviral therapy. AIDS Clin Care (2008) 0.75
Meeting report from the XV International AIDS Conference. Perinatal transmission. AIDS Clin Care (2004) 0.75
Report from the XVI International AIDS Conference. CCR5 inhibitors. AIDS Clin Care (2006) 0.75
Meeting report from the XV International AIDS Conference. Clinical trials of approved antiretrovirals. AIDS Clin Care (2004) 0.75
Report from the XVI International AIDS Conference. Efavirenz for high viral load and low CD4--a secondary analysis of ACTG 5095. AIDS Clin Care (2006) 0.75
Revised guidelines for antiretroviral use in pregnant women. AIDS Clin Care (2008) 0.75
Report from the 11th conference on retroviruses and opportunistic infections. Studies of approved antiretrovirals. AIDS Clin Care (2004) 0.75
Tolerance of efavirenz-induced central nervous system side effects in HIV-infected individuals with a history of substance abuse. HIV Clin Trials (2003) 0.75
Report from the 11th conference on retroviruses and opportunistic infections. Resistance. AIDS Clin Care (2004) 0.75